CN102716129A - Application of ligustrazine to medicines for adjuvant therapy of rheumatoid diseases - Google Patents
Application of ligustrazine to medicines for adjuvant therapy of rheumatoid diseases Download PDFInfo
- Publication number
- CN102716129A CN102716129A CN2011100757766A CN201110075776A CN102716129A CN 102716129 A CN102716129 A CN 102716129A CN 2011100757766 A CN2011100757766 A CN 2011100757766A CN 201110075776 A CN201110075776 A CN 201110075776A CN 102716129 A CN102716129 A CN 102716129A
- Authority
- CN
- China
- Prior art keywords
- ligustrazine
- application
- adjuvant therapy
- rheumatoid disease
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an application of ligustrazine to medicines for adjuvant therapy of rheumatoid diseases. The application comprises the following ratio schemes of pharmaceutical raw materials: methotrexate 1 g and ligustrazine 4-20 g; salazosulfadimidine 2 g and ligustrazine 0.4-2.0 g; tripterygium wilfordii 1 g and ligustrazine 0.4-2.0 g; cyclophosphamide 1 g and ligustrazine 0.4-2.0 g; leflunomide 1 g and ligustrazine 4-20 g; azathioprine 2 g and ligustrazine 0.2-1.8 g; penicillamine 2.5 g and ligustrazine 0.4-2.0 g; and hydroxychloroquine 4 g and ligustrazine 0.4-2.0 g. The preparation method is that mixing and making two pharmaceutical raw materials into powder, adding routine pharmaceutic adjuvants, and making the powder with adjuvants into tablets or injections through a routine preparation technology. The application initiates a new usage of the ligustrazine in medicines and has obvious effects when cooperating with mainstream medicines for treating rheumatoid diseases, such as methotrexate, salazosulfadimidine, etc. The application contributes greatly to the treatment of stubborn rheumatoid diseases.
Description
Technical field
The present invention relates to new purposes, the particularly ligustrazine application in the adjuvant therapy rheumatoid disease medicament of known substance ligustrazine.
Background technology
Atrophic diseases is one type of disease that the clinical onset rate is higher, hazardness is bigger.Many rheumatoid disease belong to clinical difficult serious symptom, and some sick disability rate is high, and some sick oncoming force is dangerous, threat to life.And it all can be fallen ill in each age group crowd, and sickness rate increases with age growth.
Methotrexate, salazosulfadimidine, Radix Tripterygii Wilfordii, cyclophosphamide etc. are the main medicines of treatment atrophic diseases; But because rheumatoid disease belongs to clinical difficult serious symptom; A lot of pathogeny are not quite clear; Even in treatment, strengthen and prolong the consumption of methotrexate, salazosulfadimidine, Radix Tripterygii Wilfordii, cyclophosphamide etc., still there is considerable patient's disease to mustn't go to effective alleviation, bring great misery to patient.
Ligustrazine has the effect of blood circulation promoting and blood stasis dispelling, antiinflammatory, antioxidation, cell proliferation to know for many medical personnels and patient.But do not see that as yet ligustrazine is in adjuvant therapy rheumatoid disease Application for Field.
Ligustrazine does not have the report of this respect at present as significant association degree not between the medicine of blood circulation promoting and blood stasis dispelling, antiinflammatory, antioxidation, cell proliferation and the treatment atrophic diseases yet.
Summary of the invention
The object of the present invention is to provide new purposes, the particularly ligustrazine application in the adjuvant therapy rheumatoid disease medicament of known substance ligustrazine.
The drug preparation technique scheme of the treatment atrophic diseases that the present invention makes is following:
Scheme one: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: methotrexate 1g, ligustrazine 4-20g; Wherein method for preparing is to process two kinds of medicament mixed Powdered; Add conventional pharmaceutic adjuvant, adopt conventional preparation technology, process tablet or injection.
Scheme two: the pharmaceutical preparation of treatment atrophic diseases; The weight proportion that comprises following medicine: salazosulfadimidine 2g; Ligustrazine 0.4-2.0g, wherein method for preparing is two kinds of medicament mixed to be processed Powdered, adds conventional pharmaceutic adjuvant; Adopt conventional preparation technology, process tablet or injection.
Scheme three: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: Radix Tripterygii Wilfordii 1g, ligustrazine 0.4-2.0g; Wherein method for preparing is to process two kinds of medicament mixed Powdered; Add conventional pharmaceutic adjuvant, adopt conventional preparation technology, process tablet or injection.
Scheme four: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: cyclophosphamide 1g, ligustrazine 0.4-2.0g; Wherein method for preparing is to process two kinds of medicament mixed Powdered; Add conventional pharmaceutic adjuvant, adopt conventional preparation technology, process tablet or injection.
Scheme five: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: leflunomide 1g, ligustrazine 4-20g; Wherein method for preparing is to process two kinds of medicament mixed Powdered; Add conventional pharmaceutic adjuvant, adopt conventional preparation technology, process tablet or injection.
Scheme six: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: azathioprine 2g, ligustrazine 0.2-1.8g; Wherein method for preparing is to process two kinds of medicament mixed Powdered; Add conventional pharmaceutic adjuvant, adopt conventional preparation technology, process tablet or injection.
Scheme seven: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: penicillamine 2.5g, ligustrazine 0.4-2.0g; Wherein method for preparing is to process two kinds of medicament mixed Powdered; Add conventional pharmaceutic adjuvant, adopt conventional preparation technology, process tablet or injection.
Scheme eight: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: oxychloroquine 4g, ligustrazine 0.4-2.0g; Wherein method for preparing is to process two kinds of medicament mixed Powdered; Add conventional pharmaceutic adjuvant, adopt conventional preparation technology, process tablet or injection.
Specific embodiment:
Embodiment 1: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: methotrexate 1g, ligustrazine 4g; Wherein method for preparing is to process two kinds of medicament mixed Powdered; Add conventional pharmaceutic adjuvant, adopt conventional preparation technology, process tablet or injection.
Embodiment 2: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: methotrexate 1g, and ligustrazine 12g, wherein method for preparing is with embodiment 1.
Embodiment 3: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: methotrexate 1g, and ligustrazine 20g, wherein method for preparing is with embodiment 1.
Embodiment 4: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: salazosulfadimidine 2g, and ligustrazine 0.4g, wherein method for preparing is with embodiment 1.
Embodiment 5: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: salazosulfadimidine 2g, and ligustrazine 1.2g, wherein method for preparing is with embodiment 1.
Embodiment 6: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: salazosulfadimidine 2g, and ligustrazine 2.0g, wherein method for preparing is with embodiment 1.
Embodiment 7: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: Radix Tripterygii Wilfordii 1g, and ligustrazine 0.4g, wherein method for preparing is with embodiment 1.
Embodiment 8: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: Radix Tripterygii Wilfordii 1g, and ligustrazine 1.2g, wherein method for preparing is with embodiment 1.
Embodiment 9: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: Radix Tripterygii Wilfordii 1g, and ligustrazine 2.0g, wherein method for preparing is with embodiment 1.
Embodiment 10: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: cyclophosphamide 1g, and ligustrazine 0.4g, wherein method for preparing is with embodiment 1.
Embodiment 11: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: cyclophosphamide 1g, and ligustrazine 1.2g, wherein method for preparing is with embodiment 1.
Embodiment 12: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: cyclophosphamide 1g, and ligustrazine 2.0g, wherein method for preparing is with embodiment 1.
Embodiment 13: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: leflunomide 1g, and ligustrazine 4g, wherein method for preparing is with embodiment 1.
Embodiment 14: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: leflunomide 1g, and ligustrazine 12g, wherein method for preparing is with embodiment 1.
Embodiment 15: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: leflunomide 1g, and ligustrazine 20g, wherein method for preparing is with embodiment 1.
Embodiment 16: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: azathioprine 2g, and ligustrazine 0.2g, wherein method for preparing is with embodiment 1.
Embodiment 17: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: azathioprine 2g, and ligustrazine 1.0g, wherein method for preparing is with embodiment 1.
Embodiment 18: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: azathioprine 2g, and ligustrazine 1.8g, wherein method for preparing is with embodiment 1.
Embodiment 19: treats the pharmaceutical preparation of atrophic diseases, comprises the weight proportion of following medicine: penicillamine 2.5g, and ligustrazine 0.4g, wherein method for preparing is with embodiment 1.
Embodiment 20: treats the pharmaceutical preparation of atrophic diseases, comprises the weight proportion of following medicine: penicillamine 2.5g, and ligustrazine 1.2g, wherein method for preparing is with embodiment 1.
Embodiment 21: treats the pharmaceutical preparation of atrophic diseases, comprises the weight proportion of following medicine: penicillamine 2.5g, and ligustrazine 2.0g, wherein method for preparing is with embodiment 1.
Embodiment 22: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: oxychloroquine 4g, and ligustrazine 0.4g, wherein method for preparing is with embodiment 1.
Embodiment 23: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: oxychloroquine 4g, and ligustrazine 1.2g, wherein method for preparing is with embodiment 1.
Embodiment 24: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: oxychloroquine 4g, and ligustrazine 2.0g, wherein method for preparing is with embodiment 1.
Embodiment 25: the pharmaceutical preparation of treatment atrophic diseases; The weight proportion that comprises following medicine: sinomenine 2g, chlorogenic acid 5g, ligustrazine are 3g; Wherein method for preparing is processed three kinds of medicament mixed Powdered; Add conventional pharmaceutic adjuvant, adopt conventional preparation technology, process tablet or injection.
Embodiment 26: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: sinomenine 2g, and chlorogenic acid 5g, ligustrazine are 5g, wherein method for preparing is with embodiment 25.
Embodiment 27: treat the pharmaceutical preparation of atrophic diseases, comprise the weight proportion of following medicine: sinomenine 2g, and chlorogenic acid 5g, ligustrazine are 7g, wherein method for preparing is with embodiment 25.
Embodiment 28: the pharmaceutical preparation of treatment atrophic diseases, only with ligustrazine 5g as raw material, wherein method for preparing is processed ligustrazine Powdered, adds the pharmaceutic adjuvant of routine, adopts conventional preparation technology, processes tablet or injection.
Embodiment 29: the hybrid medicine powder that embodiment 1-28 processes, with starch and dextrin mix homogeneously, process tablet according to the conventional tablet preparation method, wherein each components contents is following:
Composition weight (part)
Hybrid medicine powder 25
Starch 25
Dextrin 7
Carboxymethyl starch sodium 7
Magnesium stearate 1
All the other are with embodiment 1-28.
Embodiment 30: the hybrid medicine powder embodiment 1-28 processes, add the injection water, and process injection according to conventional injection preparation method, wherein each components contents is following:
Composition weight (part)
Hybrid medicine powder 150
Sodium chloride 50
Water for injection 1000
Efficacy experiment:
(1) 300 rheumatoid arthritis patients is divided into A, B, C, D, E, F, G, H, I, J10 group; Every group 30 people; The oral respectively medicament mixed powder of processing by embodiment 2,5,8,11,14,17,20,23,26,28; One day twice, to take continuously three months, effect is as shown in the table:
(2) get 350 of healthy normal SD rats, random choose wherein 10 all the other rats are accepted the CFA modeling as normal group, modeling was selected 290 of the tangible rats of secondary affection on the 30th day and is divided into groups, and 10 every group, was divided into 29 groups at random.The hybrid medicine powder of the treatment rheumatoid arthritis that is made by embodiment 1 to 28 is given 28 groups of rat feedings with the oral dose of 30mg/kg respectively, remaining one group as model group.By the curative effect of 1 day, 10 days, 20 days, 30 days inspection Drug therapy rheumatoid arthritis, this experiment is similar to the experiment of the joint pathology damage that rat is carried out, and for referencial use with the comprehensive score of its joint pathology damage sxemiquantitative.Effect of drugs is following:
Embodiment 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24 contrasts with model group respectively, and the 10th day decline scope of the comprehensive score of joint pathology damage sxemiquantitative is all at 2-5%.
Embodiment 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24 contrasts with model group respectively, and the 20th day decline scope of the comprehensive score of joint pathology damage sxemiquantitative is all at 5-10%.
Embodiment 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24 contrasts with model group respectively, and the 30th day decline scope of the comprehensive score of joint pathology damage sxemiquantitative is all at 12-20%.
Embodiment 25,26,27,28 contrasts with model group respectively, and the 10th day decline scope of the comprehensive score of joint pathology damage sxemiquantitative is all at 0-5%.
Embodiment 25,26,27,28 contrasts with model group respectively, and the 20th day decline scope of the comprehensive score of joint pathology damage sxemiquantitative is all at 0-5%.
Embodiment 25,26,27,28 contrasts with model group respectively, and the 20th day decline scope of the comprehensive score of joint pathology damage sxemiquantitative is all at 0-10%.
Obtain following results in conjunction with above-mentioned result of the test:
1, use ligustrazine treatment rheumatoid disease effect undesirable separately.
2, ligustrazine cooperates the rheumatoid medicine methotrexate of treatment of main flow, and salazosulfadimidine, Radix Tripterygii Wilfordii, cyclophosphamide, leflunomide, azathioprine, penicillamine, oxychloroquine effect are obvious.This is huge for the obstinate rheumatoid contribution of treatment.
3, use methotrexate separately; When salazosulfadimidine, Radix Tripterygii Wilfordii, cyclophosphamide, leflunomide, azathioprine, penicillamine, oxychloroquine are treated rheumatoid medicine; Therapeutic effect on statistics not as ligustrazine respectively with methotrexate, salazosulfadimidine, Radix Tripterygii Wilfordii, cyclophosphamide, leflunomide, azathioprine, penicillamine, oxychloroquine are united the good effect of use.
4, comprehensively above-mentioned, ligustrazine has the effect of adjuvant therapy rheumatoid disease, and the application of ligustrazine in the adjuvant therapy rheumatoid disease medicament has foundation.
Claims (10)
1. the application of ligustrazine in the adjuvant therapy rheumatoid disease medicament, comprise ligustrazine respectively with main flow treatment rheumatoid medicine methotrexate, salazosulfadimidine, Radix Tripterygii Wilfordii, cyclophosphamide, leflunomide, azathioprine, penicillamine, oxychloroquine Combined application in the treatment atrophic diseases.
2. the application of ligustrazine as claimed in claim 1 in the adjuvant therapy rheumatoid disease medicament is characterized by the medicine material of following weight proportioning: methotrexate 1g, ligustrazine 4-20g.
3. the application of ligustrazine as claimed in claim 1 in the adjuvant therapy rheumatoid disease medicament is characterized by the medicine material of following weight proportioning: salazosulfadimidine 2g, ligustrazine 0.4-2.0g.
4. the application of ligustrazine as claimed in claim 1 in the adjuvant therapy rheumatoid disease medicament is characterized by the medicine material of following weight proportioning: Radix Tripterygii Wilfordii 1g, ligustrazine 0.4-2.0g.
5. the application of ligustrazine as claimed in claim 1 in the adjuvant therapy rheumatoid disease medicament is characterized by the medicine material of following weight proportioning: cyclophosphamide 1g, ligustrazine 0.4-2.0g.
6. the application of ligustrazine as claimed in claim 1 in the adjuvant therapy rheumatoid disease medicament is characterized by the medicine material of following weight proportioning: leflunomide 1g, ligustrazine 4-20g.
7. the application of ligustrazine as claimed in claim 1 in the adjuvant therapy rheumatoid disease medicament is characterized by the medicine material of following weight proportioning: azathioprine 2g, ligustrazine 0.2-1.8g.
8. the application of ligustrazine as claimed in claim 1 in the adjuvant therapy rheumatoid disease medicament is characterized by the medicine material of following weight proportioning: penicillamine 2.5g, ligustrazine 0.4-2.0g.
9. the application of ligustrazine as claimed in claim 1 in the adjuvant therapy rheumatoid disease medicament is characterized by the medicine material of following weight proportioning: oxychloroquine 4g, ligustrazine 0.4-2.0g.
10. like the application of the described ligustrazine of claim 1-9 in the adjuvant therapy rheumatoid disease medicament; It is characterized by: method for preparing is to process two kinds of medicament mixed Powdered; Add conventional pharmaceutic adjuvant, adopt conventional preparation technology, process tablet or injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110075776.6A CN102716129B (en) | 2011-03-29 | 2011-03-29 | Application of ligustrazine to medicines for adjuvant therapy of rheumatoid diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110075776.6A CN102716129B (en) | 2011-03-29 | 2011-03-29 | Application of ligustrazine to medicines for adjuvant therapy of rheumatoid diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102716129A true CN102716129A (en) | 2012-10-10 |
| CN102716129B CN102716129B (en) | 2014-10-15 |
Family
ID=46942087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110075776.6A Expired - Fee Related CN102716129B (en) | 2011-03-29 | 2011-03-29 | Application of ligustrazine to medicines for adjuvant therapy of rheumatoid diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102716129B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1964730A (en) * | 2004-06-09 | 2007-05-16 | 深圳市前仁人科技开发有限公司 | Herbal compositions for prevention and treatment rheumatic and inflammatory diseases and method of preparing the same |
| CN101411707A (en) * | 2008-10-10 | 2009-04-22 | 西南大学 | Pharmaceutical composition for treating rheumatoid arthritis |
-
2011
- 2011-03-29 CN CN201110075776.6A patent/CN102716129B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1964730A (en) * | 2004-06-09 | 2007-05-16 | 深圳市前仁人科技开发有限公司 | Herbal compositions for prevention and treatment rheumatic and inflammatory diseases and method of preparing the same |
| CN101411707A (en) * | 2008-10-10 | 2009-04-22 | 西南大学 | Pharmaceutical composition for treating rheumatoid arthritis |
Non-Patent Citations (3)
| Title |
|---|
| 王建杰等: "川芎嗪对类风湿性关节炎大鼠关节滑液骨保护素表达的影响", 《黑龙江医药科学》 * |
| 王建杰等: "川芎嗪对类风湿性关节炎患者外周血单个核细胞IL-12mRNA表达的影响", 《黑龙江医药科学》 * |
| 马寿萍等: "大剂量川芎嗪注射液治疗类风湿性关节炎的护理体会", 《遵义医学院学报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102716129B (en) | 2014-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103768123A (en) | Traditional Chinese medicine composition and preparation method thereof | |
| CN103861079A (en) | Traditional Chinese medicine composition with effects of clearing heat, relieving pain and eliminating tumors | |
| CN102772611B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN102240345A (en) | Compound Chinese herbal medicine preparation for preventing and treating Newcastle disease | |
| CN102824414B (en) | Medicinal tea used for treating constipation | |
| CN102657705A (en) | Medicine for treating tympanitis and preparation method thereof | |
| CN102406778B (en) | Traditional Chinese medicine composition for treating Alzheimer type dementia and preparation method thereof | |
| CN102716129B (en) | Application of ligustrazine to medicines for adjuvant therapy of rheumatoid diseases | |
| CN1990033A (en) | Drug for treating hypertension, dense blood and arteriosclerosis | |
| CN102430000A (en) | Traditional Chinese medicinal composition for treating Alzheimer-type disease and preparation method thereof | |
| CN102846928A (en) | A Chinese medicinal formulation for treating coronary heart disease | |
| CN102949712A (en) | Chinese and western composite medicine for treating neoplastic diseases | |
| CN104706728A (en) | Combinatorial medicament used for treating piglet intestinal infection and preparation method thereof | |
| CN103006622B (en) | New borneol use and lung cancer treatment drug composition | |
| CN104127532B (en) | The application of a kind of NAOXINTONG JIAONANG in preparation treatment oncosis medicine | |
| CN105079141B (en) | A kind of Tibetan veterinary medicine composition for treating yak pneumonia and its preparation method and application | |
| CA2897813A1 (en) | Method and composition for treatment of arthritis and osteoarthrosis | |
| CN107802681B (en) | Composition for improving clinical symptom sign of HIV infected person | |
| CN102579617A (en) | Traditional Chinese medicine capsule for treating chronic neck, shoulder, waist and leg pains and processing method of same | |
| CN102846781A (en) | Veterinary drug containing Chinese medicines for treating coccidiosis in poultry | |
| CN1277570C (en) | Pharmaceutical for treating alimentary tract ulcer disease and preparing process thereof | |
| CN101628044A (en) | Medicine for treating esophagus cancer and preparation method thereof | |
| CN1297297C (en) | Traditional Chinese medicine composition, its preparation method and application for preparing medicine to treat cancer | |
| CN104225056A (en) | Drug for treating rheumatic arthritis | |
| CN104161791A (en) | Traditional Chinese medicine composition for treating cervical and lumbar spondylosis as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141015 Termination date: 20180329 |